# Pulmonary sarcomatoid_MEDI4736+Treme

> **NCT03022500** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 32 (actual)

## Conditions studied

- Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC

## Interventions

- **DRUG:** durvalumab + tremelimumab

## Key facts

- **NCT ID:** NCT03022500
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-18
- **Primary completion:** 2018-02-28
- **Final completion:** 2019-11-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03022500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03022500, "Pulmonary sarcomatoid_MEDI4736+Treme". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03022500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*